



U.S.S.N. 10/036,819

Atty. Dkt. No. 032026-0700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hayes et al.

Title: Use of Biologically Active Vitamin D Compounds for the Prevention and Treatment of Inflammatory Bowel Disease

Appl. No.: 10/036,819

Filing Date: 12/21/2001

Examiner: S. N. Qazi

Art Unit: 1616

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

Bernard P. Friedrichsen
(Printed Name)

[Signature]
(Signature)

April 15, 2003
(Date of Deposit)

#6
5/1/03

RECEIVED
APR 24 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of

04/22/2003 HGUTENA1 00000078 10036819

01 FC:1806

180.00 OP

003.421756.1

allowance under 37 CFR § 1.113, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

An English translation of the single foreign-language document is not readily available. However, an English-language abstract of the foreign language document is included on the second page of the foreign language document. The absence of a complete translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR § 1.98 and MPEP § 609).

Applicants respectfully request that each of the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP § 609.

FEE

A check for the fee in connection with submission of a supplemental information disclosure statement under 37 CFR § 1.97(c) in the amount of \$180.00 in accordance with 37 CFR § 1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date

April 15, 2003

By

Bernard P. Friedrichsen

FOLEY & LARDNER

Customer Number: 23524



23524

PATENT TRADEMARK OFFICE

Telephone: (608) 258-4281

Facsimile: (608) 258-4258

Bernard P. Friedrichsen
Attorney for Applicant
Registration No. 44,689